These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24596469)

  • 21. Duloxetine versus other anti-depressive agents for depression.
    Cipriani A; Koesters M; Furukawa TA; Nosè M; Purgato M; Omori IM; Trespidi C; Barbui C
    Cochrane Database Syst Rev; 2012 Oct; 10():CD006533. PubMed ID: 23076926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Duloxetine compliance and its association with healthcare costs among patients with diabetic peripheral neuropathic pain.
    Wu N; Chen S; Boulanger L; Fraser K; Bledsoe SL; Zhao Y
    J Med Econ; 2009 Sep; 12(3):192-202. PubMed ID: 19705975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Healthcare Costs and Medication Adherence Among Patients with Fibromyalgia: Combination Medication vs. Duloxetine, Milnacipran, Venlafaxine, and Pregabalin Initiators.
    Marlow NM; Simpson KN; Vaughn IA; Jo A; Zoller JS; Short EB
    Pain Pract; 2018 Feb; 18(2):154-169. PubMed ID: 28419725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Real-World, Prospective, Multicenter, Single-Arm Observational Study of Duloxetine in Patients With Major Depressive Disorder or Generalized Anxiety Disorder.
    Szekeres G; Rozsa S; Dome P; Barsony G; Gonda X
    Front Psychiatry; 2021; 12():689143. PubMed ID: 34220591
    [No Abstract]   [Full Text] [Related]  

  • 25. Predictors of duloxetine adherence and persistence in patients with fibromyalgia.
    Cui Z; Zhao Y; Novick D; Faries D
    J Pain Res; 2012; 5():193-201. PubMed ID: 22792005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A retrospective pooled analysis of duloxetine safety in 23,983 subjects.
    Gahimer J; Wernicke J; Yalcin I; Ossanna MJ; Wulster-Radcliffe M; Viktrup L
    Curr Med Res Opin; 2007 Jan; 23(1):175-84. PubMed ID: 17257478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
    Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
    Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine.
    Rodrigues-Amorim D; Olivares JM; Spuch C; Rivera-Baltanás T
    Front Psychiatry; 2020; 11():554899. PubMed ID: 33192668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adherence and persistence with duloxetine and hospital utilization in patients with major depressive disorder.
    Liu X; Tepper PG; Able SL
    Int Clin Psychopharmacol; 2011 May; 26(3):173-80. PubMed ID: 21278576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Duloxetine in the treatment of major psychiatric and neuropathic disorders.
    Müller N; Schennach R; Riedel M; Möller HJ
    Expert Rev Neurother; 2008 Apr; 8(4):527-36. PubMed ID: 18416656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Duloxetine in Patients with Chronic Pain Conditions.
    Skljarevski V; Zhang S; Iyengar S; D'Souza D; Alaka K; Chappell A; Wernicke J
    Curr Drug ther; 2011 Nov; 6(4):296-303. PubMed ID: 22876216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.
    Arnold LM; Hudson JI; Wang F; Wohlreich MM; Prakash A; Kajdasz DK; Chappell AS
    Clin J Pain; 2009; 25(6):461-8. PubMed ID: 19542792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dosing patterns for duloxetine and predictors of high-dose prescriptions in patients with major depressive disorder: analysis from a United States third-party payer perspective.
    Liu X; Cui Z; Niu L; Faries DE; Ball T; Johnstone B
    Clin Ther; 2011 Nov; 33(11):1726-38. PubMed ID: 22019345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dosing pattern comparison between duloxetine and pregabalin among patients with diabetic peripheral neuropathic pain.
    Sun P; Zhao Y; Zhao Z; Bernauer M; Watson P
    Pain Pract; 2012 Nov; 12(8):641-8. PubMed ID: 22335435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?
    Perahia DG; Pritchett YL; Desaiah D; Raskin J
    Int Clin Psychopharmacol; 2006 Nov; 21(6):311-7. PubMed ID: 17012978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of direct analgesic effect of duloxetine for chronic low back pain: post hoc path analysis of double-blind, placebo-controlled studies.
    Enomoto H; Fujikoshi S; Funai J; Sasaki N; Ossipov MH; Tsuji T; Alev L; Ushida T
    J Pain Res; 2017; 10():1357-1368. PubMed ID: 28615967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder.
    Liu X; Chen Y; Faries DE
    Clinicoecon Outcomes Res; 2011; 3():63-72. PubMed ID: 21935334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Duloxetine and pregnancy outcomes: safety surveillance findings.
    Hoog SL; Cheng Y; Elpers J; Dowsett SA
    Int J Med Sci; 2013; 10(4):413-9. PubMed ID: 23471302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of Duloxetine in Chronic Low Back Pain with a Neuropathic Component: A Randomized, Double-blind, Placebo-controlled Crossover Trial.
    Schukro RP; Oehmke MJ; Geroldinger A; Heinze G; Kress HG; Pramhas S
    Anesthesiology; 2016 Jan; 124(1):150-8. PubMed ID: 26517858
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.